Allogeneic transplantation for lymphoma

Journal of Clinical Oncology

Volumn 29, Issue 14, 2011, Pages 1855-1863

  Chakraverty, Ronjon ^a   Mackinnon, Stephen ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; RITUXIMAB; THIOTEPA; THYMOCYTE ANTIBODY;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; BURKITT LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER MORTALITY; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LYMPHOMA EFFECT; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LONG TERM CARE; LYMPHOMA; MANTLE CELL LYMPHOMA; MYCOSIS FUNGOIDES; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; SEZARY SYNDROME; SURVIVAL RATE; T CELL LYMPHOMA; THERAPY EFFECT; TREATMENT OUTCOME;

GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 79955802507     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.8419     Document Type: Review

References (83)

1. Friedberg JW: Treatment of follicular non-Hodgkin's lymphoma: The old and the new. Semin Hematol 45:S2-S6, 2008
2. Akpek G, Ambinder RF, Piantadosi S, et al: Longterm results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 19:4314-4321, 2001 (Pubitemid 33096779)
3. Anderson JE, Litzow MR, Appelbaum FR, et al: Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience. J Clin Oncol 11:2342-2350, 1993 (Pubitemid 23353963)
4. Gajewski JL, Phillips GL, Sobocinski KA, et al: Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 14:572-578, 1996 (Pubitemid 26051023)
5. Milpied N, Fielding AK, Pearce RM, et al: Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease: European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 14:1291-1296, 1996 (Pubitemid 26105538)
6. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al: An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31:667-678, 2003 (Pubitemid 36553477)
7. van Besien K, Loberiza FR Jr, Bajorunaite R, et al: Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102:3521-3529, 2003 (Pubitemid 37409366)
8. Dreger P: Allotransplantation for chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 602-609, 2009
9. Forman SJ: Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults. Hematol Oncol Clin North Am 23:1011-1031, 2009
10. Goldstone AH, Rowe JM: Transplantation in adult ALL. Hematology Am Soc Hematol Educ Program 593-601, 2009
11. Gribben JG: Stem cell transplantation in chronic lymphocytic leukemia. Biol Blood Marrow Transplant 15:53-58, 2009
12. Bierman PJ, Sweetenham JW, Loberiza FR Jr, et al: Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: A comparison with allogeneic and autologous transplantation - The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 21:3744-3753, 2003 (Pubitemid 46606228)
13. Lazarus HM, Zhang MJ, Carreras J, et al: A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: A report from the CIBMTR. Biol Blood Marrow Transplant 16:35-45, 2010
14. Maris MB, Sandmaier BM, Storer BE, et al: Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104:3535-3542, 2004 (Pubitemid 39564424)
15. Rezvani AR, Storer B, Maris M, et al: Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 26:211-217, 2008
16. Kohrt HE, Turnbull BB, Heydari K, et al: TLI and ATG conditioning with low risk of graft-versushost disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 114:1099-1109, 2009
17. Anderlini P, Saliba R, Acholonu S, et al: Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: The updated M.D. Anderson Cancer Center experience. Haematologica 93:257-264, 2008 (Pubitemid 351397714)
18. Thomson KJ, Morris EC, Milligan D, et al: T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 28:3695-3700, 2010
19. Sorror ML, Storer BE, Maloney DG, et al: Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 111:446-452, 2008
20. Sureda A, Robinson S, Canals C, et al: Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26:455-462, 2008 (Pubitemid 351171699)
21. Hari P, Carreras J, Zhang MJ, et al: Allogeneic transplants in follicular lymphoma: Higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 14:236-245, 2008
22. Rodriguez R, Nademanee A, Ruel N, et al: Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 12:1326-1334, 2006 (Pubitemid 44858267)
23. Chakraverty R, Peggs K, Chopra R, et al: Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99:1071-1078, 2002 (Pubitemid 34525573)
24. Kottaridis PD, Milligan DW, Chopra R, et al: In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96:2419-2425, 2000
25. Bloor AJ, Thomson K, Chowdhry N, et al: High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant 14:50-58, 2008 (Pubitemid 350286737)
26. Peggs KS, Thomson K, Hart DP, et al: Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: Toxicity, chimerism, and disease responses. Blood 103:1548-1556, 2004 (Pubitemid 38168677)
27. Bethge WA, Lange T, Meisner C, et al: Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: Results of a phase 2 study. Blood 116:1795-1802, 2010
28. Kyriakou C, Canals C, Finke J, et al: Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: A retrospective study from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 27:3951-3958, 2009
29. Robinson SP, Sureda A, Canals C, et al: Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: Identification of prognostic factors predicting outcome. Haematologica 94:230-238, 2009
30. Sureda A, Canals C, Arranz R, et al: Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma: Final analysis of the HDR-Allo Protocol - A prospective clinical trial by the Group Espanol de Linfomas/Trasplante de Medula Osea and the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 114:659a, 2009 (abstr)
31. Tam CS, Bassett R, Ledesma C, et al: Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113:4144-4152, 2009
32. Peggs KS, Hunter A, Chopra R, et al: Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 365:1934-1941, 2005
33. Chakraverty R, Eom HS, Sachs J, et al: Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versusleukemia responses following delayed donor leukocyte infusions. Blood 108:2106-2113, 2006 (Pubitemid 44395027)
34. Mapara MY, Kim YM, Wang SP, et al: Donor lymphocyte infusions mediate superior graft-versusleukemia effects in mixed compared to fully allogeneic chimeras: A critical role for host antigen-presenting cells. Blood 100:1903-1909, 2002
35. Thomson KJ, Morris EC, Bloor A, et al: Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 27:426-432, 2009
36. Butcher BW, Collins RH Jr: The graft-versuslymphoma effect: Clinical review and future opportunities. Bone Marrow Transplant 36:1-17, 2005 (Pubitemid 40946045)
37. Morris E, Thomson K, Craddock C, et al: Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 104:3865-3871, 2004 (Pubitemid 39620131)
38. Rizzo JD, Curtis RE, Socié G, et al: Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113:1175-1183, 2009
39. Pidala J, Anasetti C, Jim H: Quality of life after allogeneic hematopoietic cell transplantation. Blood 114:7-19, 2009
40. Sun CL, Francisco L, Kawashima T, et al: Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: A report from the Bone Marrow Transplant Survivor Study. Blood 116:3129-3139, 2010
41. Pasquini MC: Impact of graft-versus-host disease on survival. Best Pract Res Clin Haematol 21:193-204, 2008
42. Linch DC, Winfield D, Goldstone AH, et al: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 341:1051-1054, 1993 (Pubitemid 23114397)
43. Schmitz N, Pfistner B, Sextro M, et al: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 359:2065-2071, 2002 (Pubitemid 34680969)
44. Smith SM, van Besien K, Carreras J, et al: Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant 14:904-912, 2008 (Pubitemid 351985028)
45. Thomson KJ, Peggs KS, Smith P, et al: Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 41:765-770, 2008 (Pubitemid 351696339)
46. Sarina B, Castagna L, Farina L, et al: Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: A retrospective study based on the time of HLA typing and donor availability. Blood 115:3671-3677, 2010
47. Alvarez I, Sureda A, Caballero MD, et al: Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: Results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant 12: 172-183, 2006 (Pubitemid 43138012)
48. Burroughs LM, O'Donnell PV, Sandmaier BM, et al: Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 14:1279-1287, 2008
49. Corradini P, Dodero A, Farina L, et al: Allogeneic stem cell transplantation following reducedintensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: Pretransplant disease status and histotype heavily influence outcome. Leukemia 21:2316-2323, 2007 (Pubitemid 350011704)
50. Devetten MP, Hari PN, Carreras J, et al: Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 15:109-117, 2009
51. Peggs KS, Mackinnon S, Linch DC: The role of allogeneic transplantation in non-Hodgkin's lymphoma. Br J Haematol 128:153-168, 2005
52. Sousou T, Friedberg J: Rituximab in indolent lymphomas. Semin Hematol 47:133-142, 2010
53. Rohatiner AZ, Nadler L, Davies AJ, et al: Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: Long-term follow-up. J Clin Oncol 25:2554-2559, 2007 (Pubitemid 47044812)
54. Montoto S, Canals C, Rohatiner AZ, et al: Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: An EBMT registry study. Leukemia 21:2324-2331, 2007 (Pubitemid 350011705)
55. Sebban C, Brice P, Delarue R, et al: Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: A GELA study. J Clin Oncol 26:3614-3620, 2008
56. Branson K, Chopra R, Kottaridis PD, et al: Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 20:4022-4031, 2002
57. Armand P, Kim HT, Ho VT, et al: Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: Importance of histology for outcome. Biol Blood Marrow Transplant 14:418-425, 2008 (Pubitemid 351372748)
58. Ingram W, Devereux S, Das-Gupta EP, et al: Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol 141:235-243, 2008 (Pubitemid 351406220)
59. Khouri IF, McLaughlin P, Saliba RM, et al: Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111:5530-5536, 2008
60. Robinson SP, Goldstone AH, Mackinnon S, et al: Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100:4310-4316, 2002 (Pubitemid 35429668)
61. Vose JM, Bierman PJ, Loberiza FR, et al: Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: Effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant 14:36-42, 2008 (Pubitemid 350301030)
62. Zwick C, Murawski N, Pfreundschuh M: Rituximab in high-grade lymphoma. Semin Hematol 47:148-155, 2010
63. Gisselbrecht C, Glass B, Mounier N, et al: Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184-4190, 2010
64. Paltiel O, Rubinstein C, Or R, et al: Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma. Bone Marrow Transplant 31:565-569, 2003 (Pubitemid 36546834)
65. Vose JM, Bierman PJ, Anderson JR, et al: Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: Clinical course and patient follow-up. Blood 80:2142-2148, 1992
66. Rezvani AR, Norasetthada L, Gooley T, et al: Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: A multicentre experience. Br J Haematol 143:395-403, 2008
67. Sirvent A, Dhedin N, Michallet M, et al: Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: Report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Biol Blood Marrow Transplant 16:78-85, 2010
68. Geisler CH, Kolstad A, Laurell A, et al: Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112:2687-2693, 2008
69. Romaguera JE, Fayad L, Rodriguez MA, et al: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23:7013-7023, 2005
70. Cook G, Smith GM, Kirkland K, et al: Outcome following reduced intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle-cell lymphoma (MCL): A study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 16:1419-1427, 2010
71. Robinson S, Sureda A, Canals C, et al: Identification of prognostic factors predicting the outcome of reduced intensity allogeneic stem cell transplantation in mantle cell lymphoma: An analysis from the Lymphoma Working Party of the EBMT. Blood 112: 457a, 2008 (abstr)
72. Savage KJ: Peripheral T-cell lymphomas. Blood Rev 21:201-216, 2007
73. Choi I, Tanosaki R, Uike N, et al: Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: Results of prospective trials. Bone Marrow Transplant 46:116-118, 2011
74. Corradini P, Dodero A, Zallio F, et al: Graftversus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22:2172-2176, 2004 (Pubitemid 41095152)
75. Duarte RF, Canals C, Onida F, et al: Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: A retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 28:4492-4499, 2010
76. Duvic M, Donato M, Dabaja B, et al: Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sézary syndrome. J Clin Oncol 28:2365-2372, 2010
77. Okamura J, Utsunomiya A, Tanosaki R, et al: Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 105:4143-4145, 2005 (Pubitemid 40656167)
78. Shustov AR, Gooley TA, Sandmaier BM, et al: Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. Br J Haematol 150:170-178, 2010
79. Tanosaki R, Uike N, Utsunomiya A, et al: Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: Impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transplant 14:702-708, 2008 (Pubitemid 351681417)
80. Le Gouill S, Milpied N, Buzyn A, et al: Graftversus-lymphoma effect for aggressive T-cell lymphomas in adults: A study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol 26:2264-2271, 2008
81. Majhail NS, Weisdorf DJ, Wagner JE, et al: Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood 107:3804-3807, 2006
82. Schot BW, Zijlstra JM, Sluiter WJ, et al: Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 109:486-491, 2007 (Pubitemid 46105942)
83. Lambert JR, Bomanji JB, Peggs KS, et al: Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood 115:2763-2768, 2010